Eli Lilly headquarters located in Indianapolis, Indiana.
Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have been barriers to more widespread use by patients.
In August, manufacturer Eli Lilly responded by offering Zepbound vials in 2.5 milligram and 5 milligram dosage strengths through its online LillyDirect pharmacy at a discount of 50% or more compared to the list price of other GLP-1 medicines for obesity. “Our goal is to break down barriers and provide patients with safe and effective options they can rely on,” said Patrik Jonsson, president of Lilly Cardiometabolic Health and Lilly USA.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.